A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelCraig H. Moskowitz, Joachim Yahalom, Stephen D. Nimer et al.|Blood|2001Cited by 427
Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphomaEunice S. Wang, Ariela Noy, Julie Teruya‐Feldstein et al.|Cancer|2003Cited by 151
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignanciesRobert Stuver, Santosha A. Vardhana, Lorenzo Falchi et al.|Cancer Cell|2022Cited by 88
Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During AdulthoodMatthew J. Matasar, David J. Straus|JNCI Journal of the National Cancer Institute|2015Cited by 45